San Francisco, November 11, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, participated and presented today at the BIO Europe in Hamburg.
Read MoreRecardio’s Digital Platform CardioCare Rolled Out in Europe
San Francisco, November 6th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its it has rolled out its digital platform CardioCare throughout Europe to support its future clinical development programs in cardiovascular.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers
San Francisco, September 9th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.
Read MoreFirst Closings of Series B Financing Round
San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the first closings of its Series B financing round.
Read MoreRecardio presented at the Cell & Gene Therapy Conference in New York
San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.
Read More- 1
- 2
- 3
- 4
- Next Page »